WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS (CAYMAN) II L.P. reported 1 transaction at AVALYN PHARMA INC.
Review the transaction codes below to understand the nature of each event.
Filed: 5/1/2026ACC: 0001193125-26-201863
→
10% Owner
Since Apr 2026
-23.27M
Net shares
Net seller
$0.00
Total acquired
0
Open market trades
0B · 0S
3
Total transactions
1.28M acquired · 24.54M disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
+1.28M
Price / share
—
Trade value
—
% of position
New position
5/1/2026
0.00→1.28M
Total
Net shares
+1.28M
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 5/1/2026 | C · Conversion | +1.28M | — | — | New position | 0.00 | 1.28M |
| Total | +1.28M | $0.00 | ||||||
Derivative Transactions2
Series C-1 Convertible Preferred Stock
Direct
Converts to
Common Stock
1.06M shares
Shares
−20.48M
Strike price
Held after
0.00
Exercisable
—
5/1/2026
Series D Convertible Preferred Stock
Direct
Converts to
Common Stock
211.01K shares
Shares
−4.06M
Strike price
Held after
0.00
Exercisable
—
5/1/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Series C-1 Convertible Preferred Stock Direct | Common Stock1.06M shares | 5/1/2026 | C · Conversion | −20.48M | — | 0.00 | |
| Series D Convertible Preferred Stock Direct | Common Stock211.01K shares | 5/1/2026 | C · Conversion | −4.06M | — | 0.00 |